191 related articles for article (PubMed ID: 18829512)
1. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers.
Braiteh F; Soriano AO; Garcia-Manero G; Hong D; Johnson MM; Silva Lde P; Yang H; Alexander S; Wolff J; Kurzrock R
Clin Cancer Res; 2008 Oct; 14(19):6296-301. PubMed ID: 18829512
[TBL] [Abstract][Full Text] [Related]
2. Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies.
Falchook GS; Fu S; Naing A; Hong DS; Hu W; Moulder S; Wheler JJ; Sood AK; Bustinza-Linares E; Parkhurst KL; Kurzrock R
Invest New Drugs; 2013 Oct; 31(5):1192-200. PubMed ID: 23907406
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers.
Wheler JJ; Janku F; Falchook GS; Jackson TL; Fu S; Naing A; Tsimberidou AM; Moulder SL; Hong DS; Yang H; Piha-Paul SA; Atkins JT; Garcia-Manero G; Kurzrock R
Cancer Chemother Pharmacol; 2014 Mar; 73(3):495-501. PubMed ID: 24435060
[TBL] [Abstract][Full Text] [Related]
4. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Soriano AO; Yang H; Faderl S; Estrov Z; Giles F; Ravandi F; Cortes J; Wierda WG; Ouzounian S; Quezada A; Pierce S; Estey EH; Issa JP; Kantarjian HM; Garcia-Manero G
Blood; 2007 Oct; 110(7):2302-8. PubMed ID: 17596541
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer.
Chu BF; Karpenko MJ; Liu Z; Aimiuwu J; Villalona-Calero MA; Chan KK; Grever MR; Otterson GA
Cancer Chemother Pharmacol; 2013 Jan; 71(1):115-21. PubMed ID: 23053268
[TBL] [Abstract][Full Text] [Related]
6. Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes.
Voso MT; Santini V; Finelli C; Musto P; Pogliani E; Angelucci E; Fioritoni G; Alimena G; Maurillo L; Cortelezzi A; Buccisano F; Gobbi M; Borin L; Di Tucci A; Zini G; Petti MC; Martinelli G; Fabiani E; Fazi P; Vignetti M; Piciocchi A; Liso V; Amadori S; Leone G
Clin Cancer Res; 2009 Aug; 15(15):5002-7. PubMed ID: 19638460
[TBL] [Abstract][Full Text] [Related]
7. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
Garcia-Manero G; Kantarjian HM; Sanchez-Gonzalez B; Yang H; Rosner G; Verstovsek S; Rytting M; Wierda WG; Ravandi F; Koller C; Xiao L; Faderl S; Estrov Z; Cortes J; O'brien S; Estey E; Bueso-Ramos C; Fiorentino J; Jabbour E; Issa JP
Blood; 2006 Nov; 108(10):3271-9. PubMed ID: 16882711
[TBL] [Abstract][Full Text] [Related]
8. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
Issa JP; Garcia-Manero G; Huang X; Cortes J; Ravandi F; Jabbour E; Borthakur G; Brandt M; Pierce S; Kantarjian HM
Cancer; 2015 Feb; 121(4):556-61. PubMed ID: 25336333
[TBL] [Abstract][Full Text] [Related]
9. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC.
Munster P; Marchion D; Bicaku E; Lacevic M; Kim J; Centeno B; Daud A; Neuger A; Minton S; Sullivan D
Clin Cancer Res; 2009 Apr; 15(7):2488-96. PubMed ID: 19318486
[TBL] [Abstract][Full Text] [Related]
10. A phase 1 trial of the oral DNA methyltransferase inhibitor CC-486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors.
Gaillard SL; Zahurak M; Sharma A; Durham JN; Reiss KA; Sartorius-Mergenthaler S; Downs M; Anders NM; Ahuja N; Rudek MA; Azad N
Cancer; 2019 Aug; 125(16):2837-2845. PubMed ID: 31012962
[TBL] [Abstract][Full Text] [Related]
11. DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.
Khouri J; Faiman BM; Grabowski D; Mahfouz RZ; Khan SN; Wei W; Valent J; Dean R; Samaras C; Jha BK; Lazarus H; Campagnaro EL; Malek E; Reed J; Karam MA; Hamilton K; Fada S; Kalaycio M; Liu H; Sobecks R; Saunthararajah Y; Chew Y; Orloff M; Reu FJ
Semin Hematol; 2021 Jan; 58(1):45-55. PubMed ID: 33509443
[TBL] [Abstract][Full Text] [Related]
12. A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia.
Odenike O; Halpern A; Godley LA; Madzo J; Karrison T; Green M; Fulton N; Mattison RJ; Yee KW; Bennett M; Koval G; Malnassy G; Larson RA; Ratain MJ; Stock W
Invest New Drugs; 2015 Apr; 33(2):371-9. PubMed ID: 25483416
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.
Münster P; Marchion D; Bicaku E; Schmitt M; Lee JH; DeConti R; Simon G; Fishman M; Minton S; Garrett C; Chiappori A; Lush R; Sullivan D; Daud A
J Clin Oncol; 2007 May; 25(15):1979-85. PubMed ID: 17513804
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma.
Gollob JA; Sciambi CJ; Peterson BL; Richmond T; Thoreson M; Moran K; Dressman HK; Jelinek J; Issa JP
Clin Cancer Res; 2006 Aug; 12(15):4619-27. PubMed ID: 16899610
[TBL] [Abstract][Full Text] [Related]
15. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
Daud AI; Dawson J; DeConti RC; Bicaku E; Marchion D; Bastien S; Hausheer FA; Lush R; Neuger A; Sullivan DM; Munster PN
Clin Cancer Res; 2009 Apr; 15(7):2479-87. PubMed ID: 19318485
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effects of a combined 5-aza-2'deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice.
Ecke I; Petry F; Rosenberger A; Tauber S; Mönkemeyer S; Hess I; Dullin C; Kimmina S; Pirngruber J; Johnsen SA; Uhmann A; Nitzki F; Wojnowski L; Schulz-Schaeffer W; Witt O; Hahn H
Cancer Res; 2009 Feb; 69(3):887-95. PubMed ID: 19155313
[TBL] [Abstract][Full Text] [Related]
17. Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2'-deoxycytidine in glioma cells.
Oi S; Natsume A; Ito M; Kondo Y; Shimato S; Maeda Y; Saito K; Wakabayashi T
J Neurooncol; 2009 Mar; 92(1):15-22. PubMed ID: 19030781
[TBL] [Abstract][Full Text] [Related]
18. A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors.
Nelson BE; Tsimberidou AM; Fu X; Fu S; Subbiah V; Sood AK; Rodon J; Karp DD; Blumenschein G; Kopetz S; Pant S; Piha-Paul SA
Oncologist; 2023 Dec; 28(12):1100-e1292. PubMed ID: 37311055
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment.
Egger G; Aparicio AM; Escobar SG; Jones PA
Cancer Res; 2007 Jan; 67(1):346-53. PubMed ID: 17210717
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
Blum W; Klisovic RB; Hackanson B; Liu Z; Liu S; Devine H; Vukosavljevic T; Huynh L; Lozanski G; Kefauver C; Plass C; Devine SM; Heerema NA; Murgo A; Chan KK; Grever MR; Byrd JC; Marcucci G
J Clin Oncol; 2007 Sep; 25(25):3884-91. PubMed ID: 17679729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
